Tonghua Golden-Horse Pharmaceutical Industry CoLtd Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Hongjun Zhan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	18.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

CEO

Hongjun Zhan (54 yo)

4.3yrs

Tenure

CN¥960,000

Compensatie

Mr. Hongjun Zhan is General Manager of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd from August 19, 2020. He served as Non-Independent Director of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hongjun Zhan	General Manager	4.3yrs	CN¥960.00k	geen gegevens
Yu Jun	Deputy GM & CFO	18.3yrs	CN¥600.00k	geen gegevens
Yu Jing	Deputy GM & Non-Independent Director	no data	CN¥600.00k	geen gegevens
Weilin Jia	Secretary & Deputy GM	22.4yrs	CN¥480.00k	geen gegevens

18.3yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 000766 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 18.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yu Jing	Deputy GM & Non-Independent Director	1.3yrs	CN¥600.00k	geen gegevens
Xu Changyou	Chairman of the Supervisory Board	13.4yrs	geen gegevens	geen gegevens
Qibin Chen	Independent Director	6.5yrs	CN¥50.40k	geen gegevens
Yufu Zhang	Chairman	5.2yrs	CN¥900.00k	geen gegevens
Huan Wang	Non-Independent Director	5.2yrs	CN¥420.00k	geen gegevens
Yingjie Wei	Non-Independent Director	4.6yrs	geen gegevens	0.019% CN¥ 2.6m
Qiang Zhou	Non-Independent Director	4.6yrs	geen gegevens	geen gegevens
Guixia Lv	Independent Director	4.6yrs	CN¥50.40k	geen gegevens
Qiuting Yin	Supervisor	4.6yrs	geen gegevens	geen gegevens
Jindi Guo	Supervisor	4.6yrs	geen gegevens	geen gegevens
Haoyan Zhang	Non-Independent Director	1.3yrs	geen gegevens	geen gegevens
Jiajun Han	Independent Director	1.3yrs	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 000766 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Tonghua Golden-Horse Pharmaceutical Industry CoLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 17, 2024

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Approves Board Elections

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 21, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.005 in 3Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q3, 2024 Results on Oct 21, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.004 in 2Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2024 Results on Aug 21, 2024

New minor risk - Share price stability

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 17, 2024

Full year 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.03 in FY 2022)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.005 (vs CN¥0.005 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.002 in 2Q 2022)

New minor risk - Share price stability

Now 23% undervalued

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Approves Board Elections

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2023 Results on Aug 21, 2023

Now 21% undervalued after recent price drop

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 21, 2023

Now 22% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.04 in FY 2021)

Now 21% undervalued

Now 20% undervalued

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.005 (vs CN¥0.007 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.02 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.006 (vs CN¥0.004 in 1Q 2021)

High number of new and inexperienced directors

Third quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.09 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.033 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.37 loss per share (vs CN¥2.11 loss in FY 2019)

New 90-day high: CN¥4.24

New 90-day low: CN¥3.13

New 90-day low: CN¥3.56

Tibet Dechangtai Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Lhasa Yongkang Medicine Co., Ltd. from Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) for CNY 5.1 million.

Third quarter earnings released

New 90-day low: CN¥4.54

New 90-day low: CN¥4.60

New 90-day high - CN¥5.58

First half earnings released

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd